$VCEL
Vericel Corp Stock $vcel

$vcel Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000162828022020355 Filed on August 03, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$38.55M	$37.05M	$36.07M
YoY Change	11.72%	-6.26%	4.36%
Cost Of Revenue	$13.32M	$14.19M	$12.62M
YoY Change	7.33%	12.55%	8.97%
Gross Profit	$25.23M	$22.85M	$23.45M
YoY Change	14.19%	-15.07%	2.03%
Gross Profit Margin	65.45%	61.69%	65.01%
Selling, General & Admin	$26.98M	$27.14M	$25.87M
YoY Change	18.44%	3.64%	14.14%
% of Gross Profit	106.9%	118.77%	110.29%
Research & Development	$5.046M	$4.792M	$4.860M
YoY Change	17.79%	7.71%	33.88%
% of Gross Profit	20.0%	20.97%	20.72%
Depreciation & Amortization	$1.000M	$1.100M	$900.0K
YoY Change	42.86%	57.14%	12.5%
% of Gross Profit	3.96%	4.81%	3.84%
Operating Expenses	$32.02M	$31.94M	$30.73M
YoY Change	18.34%	4.23%	16.87%
Operating Profit	-$6.788M	-$9.082M	-$7.273M
YoY Change	36.83%	143.55%	120.06%
Interest Expense	$105.0K	$20.00K	$18.00K
YoY Change	10400.0%	1900.0%	1700.0%
% of Operating Profit
Other Income/Expense, Net	$232.0K	$119.0K	$182.0K
YoY Change	673.33%	693.33%	14.47%
Pretax Income	-$6.556M	-$8.963M	-$7.091M
YoY Change	32.95%	141.33%	125.4%
Income Tax	$21.00K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$6.577M	-$8.963M	-$7.091M
YoY Change	33.38%	136.74%	115.6%
Net Earnings / Revenue	-17.06%	-24.19%	-19.66%
Basic Earnings Per Share	-$0.14	-$0.19	-$0.15
Diluted Earnings Per Share	-$0.14	-$0.19	-$0.15
COMMON SHARES
Basic Shares Outstanding	47.18M shares	47.12M shares	46.99M shares
Diluted Shares Outstanding	47.18M shares	47.12M shares	46.99M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$110.9M	$100.7M	$100.5M
YoY Change	12.87%	10.68%	20.27%
Cash & Equivalents	$65.22M	$56.10M	$55.70M
Short-Term Investments	$45.72M	$44.64M	$44.89M
Other Short-Term Assets	$4.410M	$4.809M	$5.093M
YoY Change	-5.89%	68.5%	20.89%
Inventory	$16.73M	$15.93M	$14.39M
Prepaid Expenses
Receivables	$34.30M	$33.66M	$31.86M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$166.4M	$155.1M	$151.9M
YoY Change	14.78%	11.97%	19.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$58.55M	$59.50M	$59.10M
YoY Change	0.02%	1.91%	1.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$21.74M	$23.72M	$22.80M
YoY Change	7.43%	-4.46%	-12.3%
Other Assets	$1.357M	$317.0K	$317.0K
YoY Change	519.63%	50.24%	58.5%
Total Long-Term Assets	$81.64M	$89.72M	$88.41M
YoY Change	3.09%	7.55%	4.93%
TOTAL ASSETS
Total Short-Term Assets	$166.4M	$155.1M	$151.9M
Total Long-Term Assets	$81.64M	$89.72M	$88.41M
Total Assets	$248.0M	$244.8M	$240.3M
YoY Change	10.65%	10.3%	13.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.113M	$9.684M	$7.750M
YoY Change	45.52%	19.06%	-12.19%
Accrued Expenses	$13.95M	$12.13M	$10.79M
YoY Change	27.59%	9.53%	8.31%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$41.00K	$41.00K
YoY Change	0.0%	0.0%
Total Short-Term Liabilities	$27.00M	$25.01M	$21.73M
YoY Change	43.42%	4.82%	-6.45%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$21.00K	$19.00K
YoY Change	-100.0%	-66.13%	-81.0%
Other Long-Term Liabilities	$0.00	$21.00K	$19.00K
YoY Change	-100.0%	-66.13%	-66.67%
Total Long-Term Liabilities	$0.00	$21.00K	$19.00K
YoY Change	-100.0%	-66.13%	-66.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.00M	$25.01M	$21.73M
Total Long-Term Liabilities	$0.00	$21.00K	$19.00K
Total Liabilities	$70.18M	$70.00M	$67.80M
YoY Change	4.18%	-1.21%	-4.84%
SHAREHOLDERS EQUITY
Retained Earnings	-$405.9M	-$399.3M	-$390.4M
YoY Change	4.67%	4.28%	2.97%
Common Stock	$584.9M	$575.0M	$563.5M
YoY Change	7.4%	7.68%	8.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$177.8M	$174.8M	$172.5M
YoY Change
Total Liabilities & Shareholders Equity	$248.0M	$244.8M	$240.3M
YoY Change	10.65%	10.3%	13.63%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$6.577M	-$8.963M	-$7.091M
YoY Change	33.38%	136.74%	115.6%
Depreciation, Depletion And Amortization	$1.000M	$1.100M	$900.0K
YoY Change	42.86%	57.14%	12.5%
Cash From Operating Activities	$4.101M	$3.143M	$3.468M
YoY Change	12.85%	-34.04%	-65.62%
INVESTING ACTIVITIES
Capital Expenditures	-$1.409M	-$1.981M	$3.081M
YoY Change	-42.79%	-6.6%	31.5%
Acquisitions
YoY Change
Other Investing Activities	$598.0K	-$1.016M	-$7.588M
YoY Change	-460.24%	-92.08%	-152.22%
Cash From Investing Activities	-$811.0K	-$2.997M	-$10.67M
YoY Change	-69.15%	-79.95%	-187.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-312.0K	249.0K	$503.0K
YoY Change	-117.46%	-93.42%	-77.76%
NET CHANGE
Cash From Operating Activities	4.101M	3.143M	$3.468M
Cash From Investing Activities	-811.0K	-2.997M	-$10.67M
Cash From Financing Activities	-312.0K	249.0K	$503.0K
Net Change In Cash	2.978M	395.0K	-$6.698M
YoY Change	6.66%	-106.17%	-127.3%
FREE CASH FLOW
Cash From Operating Activities	$4.101M	$3.143M	$3.468M
Capital Expenditures	-$1.409M	-$1.981M	$3.081M
Free Cash Flow	$5.510M	$5.124M	$387.0K
YoY Change	-9.63%	-25.59%	-95.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000887359
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	dei	City Area Code CityAreaCode	617
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02139
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2022Q2	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35280
	dei	Entity Registrant Name EntityRegistrantName	VERICEL CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	MI
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3096597
	dei	Entity Address Address Line1 EntityAddressAddressLine1	64 Sidney Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Local Phone Number LocalPhoneNumber	588-5555
	dei	Security12b Title Security12bTitle	Common Stock (No par value)
	dei	Trading Symbol TradingSymbol	VCEL
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	47177974	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56054000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	68330000	usd
CY2022Q2	us-gaap	Short Term Investments ShortTermInvestments	44638000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	35068000	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	40000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	40000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	33664000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	37437000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	15929000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	13381000	usd
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	4809000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4246000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	155094000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	158462000	usd
CY2022Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	15919000	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	13308000	usd
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	6184000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	211000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	43583000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	45720000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	23718000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	25687000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	317000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	317000	usd
CY2022Q2	us-gaap	Assets Assets	244815000	usd
CY2021Q4	us-gaap	Assets Assets	243705000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	9684000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9016000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12133000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14045000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3156000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2950000	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	41000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	41000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	25014000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26052000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44964000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	47147000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	21000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	44000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	69999000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	73243000	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47141000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47141000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46880000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46880000	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	575011000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	553902000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-855000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-154000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-399340000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-383286000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	174816000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	170462000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	244815000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	243705000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36826000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38680000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	72678000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	72307000	usd
CY2022Q2	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	220000	usd
CY2021Q2	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	839000	usd
	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	442000	usd
	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	1780000	usd
CY2022Q2	us-gaap	Revenues Revenues	37046000	usd
CY2021Q2	us-gaap	Revenues Revenues	39519000	usd
	us-gaap	Revenues Revenues	73120000	usd
	us-gaap	Revenues Revenues	74087000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14192000	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12609000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	26814000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	24192000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	22854000	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	26910000	usd
	us-gaap	Gross Profit GrossProfit	46306000	usd
	us-gaap	Gross Profit GrossProfit	49895000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4792000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4449000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9652000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8079000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27144000	usd
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26190000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	53009000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	48850000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	31936000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	30639000	usd
	us-gaap	Operating Expenses OperatingExpenses	62661000	usd
	us-gaap	Operating Expenses OperatingExpenses	56929000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9082000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3729000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16355000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7034000	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	148000	usd
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	43000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	236000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	119000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	20000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	1000	usd
	us-gaap	Interest Expense InterestExpense	38000	usd
	us-gaap	Interest Expense InterestExpense	2000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-9000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-27000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	103000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	57000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	119000	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	15000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	301000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	174000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8963000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3714000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16054000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6860000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	72000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	215000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-8963000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3786000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16054000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7075000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47117000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46403000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47052000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46195000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47117000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46403000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47052000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46195000	shares
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-8963000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3786000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16054000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7075000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-242000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	24000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-701000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-37000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9205000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3762000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16755000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7112000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	170462000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7091000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9531000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1155000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	310000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1423000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-459000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	172485000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-8963000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10808000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	428000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	318000	usd
CY2022Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	18000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-242000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	174816000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	134260000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-3289000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7019000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3532000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	249000	usd
CY2021Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1501000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-61000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	140209000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3786000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10866000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3531000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	309000	usd
CY2021Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	61000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	24000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	563000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1039000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	151092000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16054000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7075000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1928000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1506000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	20339000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	17885000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-302000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-505000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2155000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2325000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-16000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-5000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2548000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3603000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56100000	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-3773000	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-2772000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1152000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1356000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1912000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-216000	usd
	vcel	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-1977000	usd
	vcel	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-1644000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6611000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	14855000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	34948000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	30951000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	26344000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	32655000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5062000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4461000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13666000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2757000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2211000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7621000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1441000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1562000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-18000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-16000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	752000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6043000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6303000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	18141000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68541000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33831000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62238000	usd
CY2022Q2	us-gaap	Investments Investments	68400000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51972000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	869000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	630000	usd
	vcel	Restricted Stock Held For Employee Tax Remittance Included In Accounts Payable RestrictedStockHeldForEmployeeTaxRemittanceIncludedInAccountsPayable	0	usd
	vcel	Restricted Stock Held For Employee Tax Remittance Included In Accounts Payable RestrictedStockHeldForEmployeeTaxRemittanceIncludedInAccountsPayable	61000	usd
CY2021Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	211000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56054000	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51761000	usd
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	6184000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62238000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51972000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Organization<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vericel Corporation, a Michigan corporation (together with its consolidated subsidiaries referred to herein as the Company, or Vericel), was incorporated in March 1989 and began employee-based operations in 1991. The Company is a fully-integrated, commercial-stage biopharmaceutical company and is a leader in advanced therapies for the sports medicine and severe burn care markets. Vericel currently markets two cell therapy products in the U.S., MACI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(autologous cultured chondrocytes on porcine collagen membrane) and Epicel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(cultured epidermal autografts).</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MACI is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (“TBSA”). The Company also holds an exclusive license from MediWound Ltd. (“MediWound”) for North American rights to NexoBrid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a registration-stage biological orphan product designed for the debridement of severe thermal burns. The Company operates its business primarily in the U.S. in one reportable segment — the research, product development, manufacture and distribution of cellular therapies for use in the treatment of specific diseases. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19</span></div><div style="padding-right:72pt;text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing pandemic caused by the spread of a novel strain of coronavirus (“COVID-19”) has created significant disruptions to the U.S. and global economy and has contributed to significant volatility in financial markets. The global impact of the outbreak has fluctuated since early 2020. At times, many state, local and national governments – including those in Massachusetts and Michigan, where the Company’s operations are located – have responded by issuing, extending and supplementing orders requiring quarantines, restrictions on travel, and the mandatory closure of certain non-essential businesses, among other actions. Because Vericel is deemed an essential business, the Company has been exempted from government orders requiring the closure of workplaces and the cessation of business operations. The vast majority of these restrictions have since been rescinded throughout most of the U.S. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding being an essential business, the Company’s business and operations at times have been adversely impacted by the ongoing effects of the COVID-19 pandemic. For example, as a result of periodic restrictions placed on the performance of elective surgical procedures, Vericel experienced a significant increase in cancellations of scheduled MACI procedures as well as a slowdown in new MACI orders during March and April of 2020. The widespread suspension of surgical procedures impacted the Company’s business and operations during the first and second quarters of 2020. The level and degree of restriction on elective surgeries, on the ability of patients to seek treatment and on U.S. business operations generally fluctuated throughout 2020 as COVID-19 infection rates rose and fell during the summer months and into the autumn. By the first quarter of 2021, the pandemic’s effects on the Company’s MACI business had largely dissipated. During the summer of 2021, however, the pandemic’s direct and ancillary effects again began to cause some disruption to the Company’s MACI business. Following the cessation of COVID-19-related travel restrictions in many parts of the U.S. and the availability of vaccinations in May and June 2021, some MACI patients postponed or delayed treatment. Further, surges of new COVID-19 cases during the second half of 2021 caused by the spread of the “Delta” and “Omicron” variants again caused disruptions to health care networks including restrictions on the performance of elective procedures, the availability of physicians and/or their treatment prioritizations, the level of healthcare facility staffing and, in some instances, the willingness or ability of patients to seek treatment. Consequently, and notwithstanding the widespread distribution of vaccines, these factors contributed to a slowdown of MACI procedures during the third and fourth quarters of 2021 and during the first and second quarters of 2022. Although hospitals are now better prepared for subsequent surges in COVID-19 patients, the risk remains that regional or local restrictions could again be placed on the performance of elective surgical procedures if the number of COVID-19 infections in the U.S. were to rise, or if new or existing COVID-19 variants render current vaccine treatments ineffective. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because Epicel is used almost exclusively in an emergent setting by burn centers and surgeons throughout the country, Epicel revenue and procedure volumes have been less affected by the pandemic. Nevertheless, the number of large burns and burn admissions can be affected by restrictions on human activity resulting from more severe government lockdown orders.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the outset of the pandemic, the Company put in place a comprehensive workplace protection plan, which instituted protective measures in response to COVID-19. Vericel’s workplace protection plan has closely followed guidance issued by the Centers for Disease Control and Prevention (“CDC”) and has complied with applicable federal and state law. To date, Vericel has been successful in sustaining its operations and providing MACI and Epicel to patients in need. The Company continues to </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review its policies and procedures regularly, including its workplace protection plan, as the pandemic evolves and the Company may take additional actions to the extent required.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to manufacture MACI and Epicel and is maintaining a significant safety stock of all key raw materials. Vericel does not expect that current supply chain interruptions will impact its ongoing manufacturing operations. With respect to customer delivery, MACI final product has an established shelf life of six (6) days and an established shipping shelf life of three (3) days. Currently, MACI is picked up by courier and shipped by commercial air or ground transportation to customer surgical sites. Epicel final product has an established shelf life of 48 hours and is hand carried to customer hospitals by courier. Transportation is primarily by commercial or charter airline. Although the Company has not experienced material shipping delays, significant disruption of air travel could result in the inability to deliver MACI or Epicel final products to customer sites within appropriate timeframes, which could further adversely impact the Company’s business. At this time, the Company is not aware of COVID-19 related impacts on its distributors, operations or third-party service providers’ ability to manage patient cases. The Company believes it is possible that it could experience variable business impacts, should a new resurgence of COVID-19 infections occur in the future.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Conflict in Ukraine</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current conflict between Russia and Ukraine and the related sanctions and other penalties imposed by countries across the globe against Russia are creating substantial uncertainty in the global economy and resulting in heightened inflation and supply chain disruptions. While the Company does not have operations in Russia or Ukraine and does not have exposure to distributors, or third-party service providers in Russia or Ukraine, it is unable to predict the impact that these actions will have on the global economy or on its financial condition, results of operations, and cash flows as of the date of these unaudited condensed consolidated financial statements.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022, the Company had an accumulated deficit of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$399.3 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and had a </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net loss of $16.1 million during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> June 30, 2022. The Company had cash and cash equivalents of $56.1 million and investments of $68.4 million as of June 30, 2022. The Company expects that cash from the sales of its products and existing cash, cash equivalents and investments will be sufficient to support the Company’s current operations through at least 12 months from the issuance of these condensed consolidated financial statements. The effects of the COVID-19 pandemic continue to evolve, however. To the extent the U.S. experiences a worsening in COVID-19 infections or the emergence of additional virus variants that result in more serious disease or limit the effectiveness of existing vaccines, subsequent healthcare measures – to include the postponement or cessation of elective and other surgical procedures – may cause the Company to experience a reduction in business and resulting revenue. This, consequently, may result in irrecoverable losses of customers and significantly impact the Company’s long-term liquidity, potentially requiring the Company to engage in layoffs, furloughs and/or reductions in salaries. The Company also may need to access additional capital; however, the Company may not be able to obtain financing on acceptable terms or at all, particularly in light of the impact of COVID-19 on the global economy and financial markets. The terms of any financing may adversely affect the holdings or the rights of the Company’s shareholders.</span></div>
CY2022Q2	vcel	Number Of Products NumberOfProducts	2	product
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-399300000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16100000	usd
	us-gaap	Basis Of Accounting BasisOfAccounting	Basis of Presentation<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying c</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ondensed consolidated financial statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of Vericel are unaudited and have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The preparation of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condensed consolidated financial statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expenses. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expenses. The full extent to which the COVID-19 pandemic will continue to directly or indirectly impact the Company’s business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developments that are highly uncertain, including as a result of new information that may emerge concerning the COVID-19 pandemic and the actions taken to continue to contain or treat COVID-19, as well as the economic impact on its customers. The Company has made estimates of the impact of the COVID-19 pandemic within these financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates. As of June 30, 2022, the Company has not recorded impairments to investments, inventory, other current assets or long-lived assets as a result of the COVID-19 pandemic.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited consolidated financial statements at that date, but does not include all the information and notes required by U.S. GAAP for complete financial statements. These c</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ondensed consolidated financial statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on February 24, 2022 (“Annual Report”).</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No new accounting standards were adopted during the quarter ended June 30, 2022.</span></div>
CY2022Q2	vcel	Number Of Contracted Specialty Pharmacies NumberOfContractedSpecialtyPharmacies	2	pharmacy
CY2022Q2	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	6700000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	7000000	usd
	vcel	Revenue Revenue Recognized Changein Uncollectible Analysis Percentage RevenueRevenueRecognizedChangeinUncollectibleAnalysisPercentage	0.0050
	vcel	Revenue Revenue Recognized Effect Of0.5 Change In The Estimated Uncollectible Percentage Amount RevenueRevenueRecognizedEffectOf0.5ChangeInTheEstimatedUncollectiblePercentageAmount	300000	usd
CY2022Q2	us-gaap	Revenues Revenues	37046000	usd
CY2021Q2	us-gaap	Revenues Revenues	39519000	usd
	us-gaap	Revenues Revenues	73120000	usd
	us-gaap	Revenues Revenues	74087000	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	15175000	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	12676000	usd
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	683000	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	644000	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	71000	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	61000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	15929000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	13381000	usd
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	55000	usd
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	74000	usd
CY2022Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	32169000	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	27630000	usd
CY2022Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	16250000	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	14322000	usd
CY2022Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	15919000	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	13308000	usd
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1100000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1900000	usd
CY2021Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	700000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1500000	usd
CY2022Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	3942000	usd
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	6305000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3555000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3616000	usd
CY2022Q2	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	4585000	usd
CY2021Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	3973000	usd
CY2022Q2	vcel	Accrued Expenses Other Current AccruedExpensesOtherCurrent	51000	usd
CY2021Q4	vcel	Accrued Expenses Other Current AccruedExpensesOtherCurrent	151000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12133000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14045000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	100000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	100000	usd
CY2022Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	100000	usd
CY2021Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	100000	usd
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	1700000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	3500000	usd
CY2021Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	1800000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	3700000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	100000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	100000	usd
CY2021Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	100000	usd
CY2022Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	100000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	43583000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	45720000	usd
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	55000	usd
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	73000	usd
CY2022Q2	vcel	Right Of Use Asset RightOfUseAsset	43638000	usd
CY2021Q4	vcel	Right Of Use Asset RightOfUseAsset	45793000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3156000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2950000	usd
CY2022Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	41000	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	41000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44964000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	47147000	usd
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	21000	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	44000	usd
CY2022Q2	vcel	Lease Liability Noncurrent LeaseLiabilityNoncurrent	48182000	usd
CY2021Q4	vcel	Lease Liability Noncurrent LeaseLiabilityNoncurrent	50182000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	69212000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	856000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	68356000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	68356000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	60909000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	154000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	60755000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	60755000	usd
	vcel	Debt Securities Available For Sale Contractual Maturity Period DebtSecuritiesAvailableForSaleContractualMaturityPeriod	P3Y
CY2021	vcel	Debt Securities Available For Sale Contractual Maturity Period DebtSecuritiesAvailableForSaleContractualMaturityPeriod	P3Y
CY2022Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2021Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-8963000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3786000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16054000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7075000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47117000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46403000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47052000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46195000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47117000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46403000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47052000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46195000	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15

Files In Submission

Name	View Source	Status
0001628280-22-020355-index-headers.html	Edgar Link	pending
0001628280-22-020355-index.html	Edgar Link	pending
0001628280-22-020355.txt	Edgar Link	pending
0001628280-22-020355-xbrl.zip	Edgar Link	pending
a1010formofrestrictedstock.htm	Edgar Link	pending
a1011formofnon-qualifiedst.htm	Edgar Link	pending
a105-eightamendmenttothedi.htm	Edgar Link	pending
a106-thirdamendmenttothedi.htm	Edgar Link	pending
a107formofnewhireincentive.htm	Edgar Link	pending
a108formofcurrentemployeei.htm	Edgar Link	pending
a109formofrestrictedstocku.htm	Edgar Link	pending
ex311ceocertificationq22022.htm	Edgar Link	pending
ex312cfocertificationq22022.htm	Edgar Link	pending
ex321ceoandcfosoxcertifica.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vcel-20220630.htm	Edgar Link	pending
vcel-20220630.xsd	Edgar Link	pending
vcel-20220630_cal.xml	Edgar Link	unprocessable
vcel-20220630_def.xml	Edgar Link	unprocessable
vcel-20220630_htm.xml	Edgar Link	completed
vcel-20220630_lab.xml	Edgar Link	unprocessable
vcel-20220630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VCEL
Vericel Corp Stock $vcel

2022 Q3 Form 10-Q Financial Statement

#000162828022020355 Filed on August 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL Vericel Corp Stock $vcel

2022 Q3 Form 10-Q Financial Statement

#000162828022020355 Filed on August 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL
Vericel Corp Stock $vcel